BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio (Nasdaq: BBIO) announced that the FDA has accepted its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1), with a PDUFA target action date of May 8, 2027. The FDA is not currently planning an advisory committee meeting, and BridgeBio is preparing to launch encaleret upon potential approval.
The Phase 3 CALIBRATE trial in ADH1 achieved all pre-specified primary and key secondary efficacy endpoints, showing normalization of key disease markers without calcium and vitamin D supplements and a favorable safety profile. BridgeBio is enrolling CALIBRATE-PEDS, a registrational Phase 2/3 trial in pediatric ADH1, and plans to start RECLAIM-HP, a global Phase 3 trial in chronic hypoparathyroidism, later in 2026. The company also plans to submit a European MAA in the second half of 2026 and notes that over 2,100 individuals have been diagnosed with autosomal dominant hypocalcemia in the U.S. since October 2023.
BridgeBio Pharma (Nasdaq: BBIO) reported that on July 7, 2026, its board compensation committee approved inducement equity grants of restricted stock units to 37 new employees, covering an aggregate of 83,283 common shares. One-fourth vests on August 16, 2027, then quarterly, subject to continued employment, under a board-adopted equity plan.
BridgeBio Pharma (Nasdaq: BBIO) reported new post-hoc analyses of Phase 2 and Phase 3 ATTRibute-CM data showing early and sustained kidney-related effects of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM).
Acoramidis initiation showed an acute, reversible eGFR dip of 8.5 mL/min/1.73m² with a placebo-corrected 15.5% UACR reduction by Day 28 (P<0.05). Through Month 30, an improved chronic eGFR slope of +2.47 mL/min/1.73m²/year (p<0.001) and a 13.7% sustained UACR reduction (p=0.026) were observed. Participants with larger eGFR dips had a 58% lower risk of death or cardiovascular hospitalization and 66% lower risk of hospitalization alone in the first year. No kidney-related adverse events were reported in these analyses. Acoramidis is approved as Attruby in the U.S. and as BEYONTTRA in multiple global markets, with labels specifying near-complete (≥90%) TTR stabilization.
BridgeBio (Nasdaq: BBIO) entered a preferred equity agreement with funds managed by Sixth Street and HealthCare Royalty for up to $1 billion in Series A cumulative convertible participating stock.
The shares carry a 7% initial dividend and an initial conversion price of $137.79, supporting Attruby and three potential U.S. launches within 12 months.
BridgeBio (Nasdaq: BBIO) reported Phase 3 PROPEL 3 results of oral infigratinib in children with achondroplasia, published in NEJM and presented at ICCBH 2026.
The trial met primary and key secondary endpoints, showed improved height, body proportionality and arm span, and supported planned FDA/EMA submissions starting Q3 2026.
BridgeBio Pharma (Nasdaq: BBIO) reported equity inducement grants under Nasdaq Listing Rule 5635(c)(4). On June 18, 2026, the board’s compensation committee approved restricted stock unit awards covering 66,810 shares of common stock for 30 new employees.
One-fourth vests on May 16, 2027, with the remainder vesting quarterly, subject to continued employment. The awards were granted under a plan adopted in November 2019 and amended in February and December 2023.
BridgeBio (Nasdaq: BBIO) will present additional positive data from PROPEL 3, its global Phase 3 trial of oral infigratinib in children with achondroplasia, at ICCBH 2026 in Montreal, June 27–30, 2026.
The company will also deliver one oral presentation and multiple posters on achondroplasia, hypochondroplasia, and autosomal dominant hypocalcemia (ADH1/ADH2).
BridgeBio (Nasdaq: BBIO) announced FDA acceptance and Priority Review of its NDA for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The FDA set a PDUFA target action date of November 27, 2026 and is not planning an advisory committee meeting.
In the Phase 3 FORTIFY trial, BBP-418 met all primary and secondary endpoints at the 12-month interim, with treated individuals improving while placebo recipients declined. BBP-418 has multiple FDA and EMA designations and could become the first approved therapy for LGMD2I/R9 and any LGMD form.
BridgeBio (Nasdaq: BBIO) submitted a New Drug Application to the FDA for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1).
The Phase 3 CALIBRATE trial met all primary and key secondary endpoints, with 76% on encaleret vs 4% on conventional therapy achieving target serum and urine calcium. Encaleret may be eligible for priority review, with an anticipated U.S. launch in early 2027 and an EMA MAA planned for 2H 2026. Pediatric and chronic hypoparathyroidism Phase 2/3 and Phase 3 programs are also underway.
BridgeBio Pharma (Nasdaq: BBIO) reported new Phase 3 ATTRibute-CM data showing that acoramidis increased serum transthyretin (sTTR) early and significantly reduced intra-individual sTTR variability versus placebo, both linked to lower all-cause mortality. Acoramidis also cut outpatient worsening heart failure risk by 41% and reduced cardiovascular hospitalizations by 34% versus tafamidis in an indirect comparison.
The therapy consistently blunted NT-proBNP increases, preserved Kansas City Cardiomyopathy Questionnaire scores, and improved or maintained heart failure-related health status. Acoramidis, a near-complete (≥90%) TTR stabilizer, is approved as Attruby in the US and BEYONTTRA in multiple global markets for ATTR-CM.